Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RCT001
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : 3B Future Health Fund II
Deal Size : Undisclosed
Deal Type : Financing
Roca Therapeutics Completes Seed Funding Round
Details : Company will use funds to develop its lead candidate RCT001 (Metastatic Uveal Melanoma) until IND/CTA readiness in 2023, and to expand portfolio of assets with the nomination of a second clinical candidate against Neovascular Glaucoma associated to Uveal...
Product Name : RCT001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 22, 2022
Lead Product(s) : RCT001
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : 3B Future Health Fund II
Deal Size : Undisclosed
Deal Type : Financing